



## "Why Do We Avoid Noninvasive Ventilation In The Medical ICU?"

Bob Kacmarek PhD, RRT Harvard Medical School Massachusetts General Hospital Boston, Massachusetts 12-11-15 Poland

## Conflict of Interest Disclosure Robert M Kacmarek

I disclose the following financial relationships with commercial entities that produce healthcare-related products or services relevant to the content I am presenting:

<u>Company</u>	<u>Relationship</u>	Content Area
Orange Medical	Consultant	Mechanical Ventilation
Covidien	<b>Research Grant</b>	Mechanical Ventilation
Venner Medical	<b>Research Grant</b>	Airways

## Clinicians Unwilling to Change their Practice?

Insufficient evidence based education Scientific/clinical bias Lack of financial incentives Lack of belief in the research evidence Taubes G. Science 1996;272:22-24. Whitcomb ME. Acad Med 2002;77:1067-1068 Kalassian KG et al. Crit Care 2002;6:11-14.

## Clinicians Unwilling to Change their Practice?

- Integration of innovation into practice takes 10 to 15 years!
- Innovation that makes management easier/better for clinicians is easier to integrate into practice than innovation that is better for patients!
- The use of NIV in the MICU requires more time and effort than invasive mechanical ventilation!
- Failure during initial applications!

Who – Indications for NIV **Undisputed indications** Acute Exacerbation of COPD Acute Cardiogenic Pulmonary Edema Weaning from mechanical ventilation **General Indications for Use** Postoperative respiratory failure Hypoxemic Respiratory Failure Patients with DNI Status Neurological/Neuromuscular Disease **Controversial Indications** ALI/ARDS Asthma

**NIV Acute Exacerbation of COPD** Over 20 RCT's NIV in COPD Prevents intubation Decreases length of MV Decreases ICU and Hosp stay Decreases cost Decreases mortality Ramsey, Hart Curr Opin Pulm Med 2013;19:626-630 Hess RC 2013;58:950-9971 Ram Cochrane Syst Rev 2004;1:CD004104

## **NIV Acute Exacerbation of COPD**

 Standard of Care
 Should be available as first line therapy in all setting caring for COPD patients

Masip JAMA 2005;294:3124 Mets-analysis of the use of NIV/CPAP for the management of acute cardiogenic pulmonary edema ■17 RCT's, both approaches over whelmingly positive Both avoided intubation No differences between the two approaches

**MV** and Heart Failure **CPAP** - standard NIV - ventilatory failure Intubation and invasive ventilation Active cardiac ischemia (infarction) Hemodynamic instability Arrhythmias Depressed mental status

## **NIV Acute Hypoxemic RF**

Post Operative Respiratory Failure Immunosurpressed Patients Patients Awaiting Transplantation Patients Post Lung Resection Acute Lung Injury Acute Respiratory Distress Syndrome

**NIV-Hypoxemic Respiratory Failure** Hilbert NEJM 2001;344:481 52 Immunosuppressed patients NIV vs. St Rx Required intubation, Serious complications, Died in the ICU: better with NIV p < 0.05Antonelli JAMA 2000; 283:235 40 Patients awaiting transplantation NIV vs. St Rx Intubation, Length of hospitalization, Complications, ICU mortality: better with NIV p < 0.05Squadrone ICM 2010;36:1666 ■ 40 pts Hematological Malignancy O<sub>2</sub> vs. O<sub>2</sub> + CPAP ■ ICU + inubation 2 vs. 14, p < 0.00001 Auriant AJRCCM 2001;164:1231 48 patients post lung resection ■ Intubation, Hospital mortality: better with NIV p <0.05

## Agarwal RC 2010;55:1653

Meta-analysis of the use of NIV in ARDS

## 14 RCT's includedNo difference in rate of intubation or mortality

## Schettino CCM 2008;36:459

■ 458 pt with ARF 38% failed NIV Mortality failing 47% vs. 5.4%, p < 0.0001</p> ■ 144 with hypoxemic ARF (not CHF) ■60% failed NIV, 64% (55) died CPE 18% intubated, mortality 39% COPD 24% intubated, mortality 33% Hypercapnia 38% intubated, mortality 0.0% Extubation failure 40% intubated, mortality 32%

## **Elective Extubation to NIV**

COPD, failed T-piece trial 48-72 hr after intubation Randomized to PSV vs. extubation to NIV Better outcome NIV Nava Ann Intern Med 1998; 128:721 No difference in outcome Girault AJRCCM 1999;160:86 Failed weaning trial 3 consecutive days, 50% of patients COPD, better outcome NIV Ferrier AJRCCM 2003;168:70 No difference in outcome, largest trial 13 centers 208 pts Girault 2011;184:672-679

## Pass SBT - High Risk of Reintubation

#### Nava CCM 2005;33:2465

COPD, CHF, ineffective cough and excessive secretions, > one weaning failure, more than one comorbid condition or upper airway obstruction: NIV > 8 hrs/day for 48 hrs, decreased reintubation rate

#### Ferrer AJRCCM 2006;173:164

Age > 65, Cardiac failure cause of intubation or APACHE II > 12 day of extubation: All high risk patients but mostly COPD, NIV 24 hrs

NIV decreased reintubation, less ICU/Hosp mortality Ferrer Lancet 2009;374:1082

- 106 pts, chronic RF who passed a SBT
- RF less NIV 8 (15%) vs. 25 (48%), p<0.0001</p>
- 90 day mortality less NIV 21(39%) vs 47(87%), p<0.0146</p>

### **NIV Post-Extubation Failure**

- Weaned non-COPD patients developing AHRF < 48 hours after extubation (n=81)</li>
   Reintubation 72 vs. 69%, LOS, mortality ND Keenan JAMA 2002;287:3238
- Patients AHRF (n=244), 37 centers, 8 countries

Reintubation 48% both groups
ICU mortality 25% NIV vs. 14% p=0.048
Time to intubation 12 hr NIV vs. 2.5 hr p=0.02 Esteban NEJM 2004;350:2452

### Diagnosis and Hospital Outcome: DNI/DNR patients receiving NIV



Schettino CCM 2005;33:1976

# Successful Application of NIV The Clinician

## The Ventilator The "MASK"

## **Ventilator Settings**

PEEP - initially zero Peak pressure - 5 cmH<sub>2</sub>O ■ Volume - 100-200 mL Adjust the ventilator from these basic settings based on the patients response and the goals of therapy! Strap the mask only when the patient is comfortable! Clinician time >1 hour

## Ventilator Settings

■PEEP 3-10 cmH<sub>2</sub>O to offset auto-PEEP or manage hypoxemia Peak pressure  $\leq 20 \text{ cmH}_2\text{O}$ Tidal Volume 300-500 mL ■Inspiratory time < 1.0 sec Final setting individualized based on the specific patient's response!!!

Successful Application of NPPV in Acute Respiratory Failure

PaCO<sub>2</sub> decrease
pH increase
PaO<sub>2</sub> increase

**Unsuccessful Application of NPPV** in Acute Respiratory Failure Cardiopulmonary stress unchanged  $-RR, V_{T}$ - HR, BP - accessory muscle use PaCO<sub>2</sub>/pH/ PaO<sub>2</sub> unchanged If the above unchanged in 1 - 2 hrs of NPPV, especially in hypoxemic ARF, intubate!





Oto RC 2013;58: 2027-2037 ASL5000: invasive and non-invasive modes Maquet Servo-i, Drager V500, Respironics V60, Covidien 840, General Electric Care Station, Hamilton C3 and G5, and Care Fusion AVEA Leaks BL 3-4 l/min, L1 9-10 l/min, L2 26-27 l/min, L3 36-37 l/min. Increasing (n=6) and decreasing (n=6) leaks.

Lung model I and E: R 10 and 20 cmH<sub>2</sub>O/L/sec respectively C 60 mL/cmH<sub>2</sub>O.

Lung model RR 15/mim and inspir time 0.9 sec
 PIP/PEEP 17/5 cmH<sub>2</sub>O



### Oto RC 2013;58: 2027-2037

Breaths to synchronization Auto-triggered breaths Missed triggered breaths Breaths to reestablish breathing pattern **Results:** 840 and V60 preformed best followed by Servo I, G3 and G5, then Care Station and V500 last Avea











## Humidification

Essential in acute application of NIV High flows and high  $F_1O_2$  result in dried retained secretions Use heated pass over humidifier System temperature about 30 degrees C Adjust to patient comfort Should not use an HME because of high gas flow and air leak!!!

## **Successful Use of NIV in the MICU**

Select the correct patients! Ventilator that compensates for leak well! Variety of masks and interfaces! Slow meticulous application! Spend sufficient time to insure success!

## Thank You